Loading…

In Silico Methods for the Discovery of Kv7.2/7.3 Channels Modulators: A Comprehensive Review

The growing interest in Kv7.2/7.3 agonists originates from the involvement of these channels in several brain hyperexcitability disorders. In particular, Kv7.2/7.3 mutants have been clearly associated with epileptic encephalopathies (DEEs) as well as with a spectrum of focal epilepsy disorders, ofte...

Full description

Saved in:
Bibliographic Details
Published in:Molecules (Basel, Switzerland) Switzerland), 2024-07, Vol.29 (13), p.3234
Main Authors: Stagno, Claudio, Mancuso, Francesca, Ciaglia, Tania, Ostacolo, Carmine, Piperno, Anna, Iraci, Nunzio, Micale, Nicola
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c320t-9154522012d4c194d9bb021de38e7c2eeb3601103a9abae5a18321a3da9f3c783
container_end_page
container_issue 13
container_start_page 3234
container_title Molecules (Basel, Switzerland)
container_volume 29
creator Stagno, Claudio
Mancuso, Francesca
Ciaglia, Tania
Ostacolo, Carmine
Piperno, Anna
Iraci, Nunzio
Micale, Nicola
description The growing interest in Kv7.2/7.3 agonists originates from the involvement of these channels in several brain hyperexcitability disorders. In particular, Kv7.2/7.3 mutants have been clearly associated with epileptic encephalopathies (DEEs) as well as with a spectrum of focal epilepsy disorders, often associated with developmental plateauing or regression. Nevertheless, there is a lack of available therapeutic options, considering that retigabine, the only molecule used in clinic as a broad-spectrum Kv7 agonist, has been withdrawn from the market in late 2016. This is why several efforts have been made both by both academia and industry in the search for suitable chemotypes acting as Kv7.2/7.3 agonists. In this context, in silico methods have played a major role, since the precise structures of different Kv7 homotetramers have been only recently disclosed. In the present review, the computational methods used for the design of Kv.7.2/7.3 small molecule agonists and the underlying medicinal chemistry are discussed in the context of their biological and structure-function properties.
doi_str_mv 10.3390/molecules29133234
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_81562414ff3f4ae3b8d16f1636c21cc4</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_81562414ff3f4ae3b8d16f1636c21cc4</doaj_id><sourcerecordid>3079857906</sourcerecordid><originalsourceid>FETCH-LOGICAL-c320t-9154522012d4c194d9bb021de38e7c2eeb3601103a9abae5a18321a3da9f3c783</originalsourceid><addsrcrecordid>eNplkU1vFDEMhiMEoqXwA7igSFy47DaOMx_hVi2lrGiFxMcNKcokHnZWmck2mdmq_75Dt1QITras531l-2XsNYglohanfQzkpkBZakCUqJ6wY1BSLFAo_fSv_oi9yHkrhAQFxXN2hLXWGurimP1cD_xbFzoX-RWNm-gzb2Pi44b4hy67uKd0y2PLP--rpTytlshXGzsMFDK_in4Kdowpv-dnfBX7XaINDbnbE_9K-45uXrJnrQ2ZXj3UE_bj4_n31afF5ZeL9erscuFQinGhoVCFlAKkVw608rpp5lU9YU2Vk0QNlgJAoNW2sVRYqFGCRW91i66q8YStD74-2q3Zpa636dZE25n7QUy_jE1j5wKZGopSKlBti62yhE3toWyhxNJJcE7NXu8OXrsUryfKo-nnP1AIdqA4ZYOi0nVRaVHO6Nt_0G2c0jBfek9JUYOWMwUHyqWYc6L2cUEQ5neM5r8YZ82bB-ep6ck_Kv7khne1GJeL</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3079208192</pqid></control><display><type>article</type><title>In Silico Methods for the Discovery of Kv7.2/7.3 Channels Modulators: A Comprehensive Review</title><source>PubMed (Medline)</source><source>Publicly Available Content Database</source><creator>Stagno, Claudio ; Mancuso, Francesca ; Ciaglia, Tania ; Ostacolo, Carmine ; Piperno, Anna ; Iraci, Nunzio ; Micale, Nicola</creator><creatorcontrib>Stagno, Claudio ; Mancuso, Francesca ; Ciaglia, Tania ; Ostacolo, Carmine ; Piperno, Anna ; Iraci, Nunzio ; Micale, Nicola</creatorcontrib><description>The growing interest in Kv7.2/7.3 agonists originates from the involvement of these channels in several brain hyperexcitability disorders. In particular, Kv7.2/7.3 mutants have been clearly associated with epileptic encephalopathies (DEEs) as well as with a spectrum of focal epilepsy disorders, often associated with developmental plateauing or regression. Nevertheless, there is a lack of available therapeutic options, considering that retigabine, the only molecule used in clinic as a broad-spectrum Kv7 agonist, has been withdrawn from the market in late 2016. This is why several efforts have been made both by both academia and industry in the search for suitable chemotypes acting as Kv7.2/7.3 agonists. In this context, in silico methods have played a major role, since the precise structures of different Kv7 homotetramers have been only recently disclosed. In the present review, the computational methods used for the design of Kv.7.2/7.3 small molecule agonists and the underlying medicinal chemistry are discussed in the context of their biological and structure-function properties.</description><identifier>ISSN: 1420-3049</identifier><identifier>EISSN: 1420-3049</identifier><identifier>DOI: 10.3390/molecules29133234</identifier><identifier>PMID: 38999185</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Animals ; antiepileptic ; Computer Simulation ; Convulsions &amp; seizures ; Crystal structure ; Drug Discovery - methods ; Epilepsy ; Genes ; Hormones ; Humans ; KCNQ ; KCNQ2 Potassium Channel - chemistry ; KCNQ2 Potassium Channel - genetics ; KCNQ2 Potassium Channel - metabolism ; KCNQ3 Potassium Channel - antagonists &amp; inhibitors ; KCNQ3 Potassium Channel - chemistry ; KCNQ3 Potassium Channel - genetics ; KCNQ3 Potassium Channel - metabolism ; Kinases ; Kv7 ; molecular docking ; molecular dynamics ; Mutation ; Neurological disorders ; Physiology ; Potassium ; potassium channel ; Proteins ; Structure-Activity Relationship</subject><ispartof>Molecules (Basel, Switzerland), 2024-07, Vol.29 (13), p.3234</ispartof><rights>2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c320t-9154522012d4c194d9bb021de38e7c2eeb3601103a9abae5a18321a3da9f3c783</cites><orcidid>0000-0002-6592-4373 ; 0000-0002-1359-8684 ; 0000-0002-9294-6033 ; 0000-0003-3715-8680 ; 0000-0002-7994-8253</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/3079208192/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/3079208192?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,25753,27924,27925,37012,37013,44590,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38999185$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Stagno, Claudio</creatorcontrib><creatorcontrib>Mancuso, Francesca</creatorcontrib><creatorcontrib>Ciaglia, Tania</creatorcontrib><creatorcontrib>Ostacolo, Carmine</creatorcontrib><creatorcontrib>Piperno, Anna</creatorcontrib><creatorcontrib>Iraci, Nunzio</creatorcontrib><creatorcontrib>Micale, Nicola</creatorcontrib><title>In Silico Methods for the Discovery of Kv7.2/7.3 Channels Modulators: A Comprehensive Review</title><title>Molecules (Basel, Switzerland)</title><addtitle>Molecules</addtitle><description>The growing interest in Kv7.2/7.3 agonists originates from the involvement of these channels in several brain hyperexcitability disorders. In particular, Kv7.2/7.3 mutants have been clearly associated with epileptic encephalopathies (DEEs) as well as with a spectrum of focal epilepsy disorders, often associated with developmental plateauing or regression. Nevertheless, there is a lack of available therapeutic options, considering that retigabine, the only molecule used in clinic as a broad-spectrum Kv7 agonist, has been withdrawn from the market in late 2016. This is why several efforts have been made both by both academia and industry in the search for suitable chemotypes acting as Kv7.2/7.3 agonists. In this context, in silico methods have played a major role, since the precise structures of different Kv7 homotetramers have been only recently disclosed. In the present review, the computational methods used for the design of Kv.7.2/7.3 small molecule agonists and the underlying medicinal chemistry are discussed in the context of their biological and structure-function properties.</description><subject>Animals</subject><subject>antiepileptic</subject><subject>Computer Simulation</subject><subject>Convulsions &amp; seizures</subject><subject>Crystal structure</subject><subject>Drug Discovery - methods</subject><subject>Epilepsy</subject><subject>Genes</subject><subject>Hormones</subject><subject>Humans</subject><subject>KCNQ</subject><subject>KCNQ2 Potassium Channel - chemistry</subject><subject>KCNQ2 Potassium Channel - genetics</subject><subject>KCNQ2 Potassium Channel - metabolism</subject><subject>KCNQ3 Potassium Channel - antagonists &amp; inhibitors</subject><subject>KCNQ3 Potassium Channel - chemistry</subject><subject>KCNQ3 Potassium Channel - genetics</subject><subject>KCNQ3 Potassium Channel - metabolism</subject><subject>Kinases</subject><subject>Kv7</subject><subject>molecular docking</subject><subject>molecular dynamics</subject><subject>Mutation</subject><subject>Neurological disorders</subject><subject>Physiology</subject><subject>Potassium</subject><subject>potassium channel</subject><subject>Proteins</subject><subject>Structure-Activity Relationship</subject><issn>1420-3049</issn><issn>1420-3049</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNplkU1vFDEMhiMEoqXwA7igSFy47DaOMx_hVi2lrGiFxMcNKcokHnZWmck2mdmq_75Dt1QITras531l-2XsNYglohanfQzkpkBZakCUqJ6wY1BSLFAo_fSv_oi9yHkrhAQFxXN2hLXWGurimP1cD_xbFzoX-RWNm-gzb2Pi44b4hy67uKd0y2PLP--rpTytlshXGzsMFDK_in4Kdowpv-dnfBX7XaINDbnbE_9K-45uXrJnrQ2ZXj3UE_bj4_n31afF5ZeL9erscuFQinGhoVCFlAKkVw608rpp5lU9YU2Vk0QNlgJAoNW2sVRYqFGCRW91i66q8YStD74-2q3Zpa636dZE25n7QUy_jE1j5wKZGopSKlBti62yhE3toWyhxNJJcE7NXu8OXrsUryfKo-nnP1AIdqA4ZYOi0nVRaVHO6Nt_0G2c0jBfek9JUYOWMwUHyqWYc6L2cUEQ5neM5r8YZ82bB-ep6ck_Kv7khne1GJeL</recordid><startdate>20240708</startdate><enddate>20240708</enddate><creator>Stagno, Claudio</creator><creator>Mancuso, Francesca</creator><creator>Ciaglia, Tania</creator><creator>Ostacolo, Carmine</creator><creator>Piperno, Anna</creator><creator>Iraci, Nunzio</creator><creator>Micale, Nicola</creator><general>MDPI AG</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-6592-4373</orcidid><orcidid>https://orcid.org/0000-0002-1359-8684</orcidid><orcidid>https://orcid.org/0000-0002-9294-6033</orcidid><orcidid>https://orcid.org/0000-0003-3715-8680</orcidid><orcidid>https://orcid.org/0000-0002-7994-8253</orcidid></search><sort><creationdate>20240708</creationdate><title>In Silico Methods for the Discovery of Kv7.2/7.3 Channels Modulators: A Comprehensive Review</title><author>Stagno, Claudio ; Mancuso, Francesca ; Ciaglia, Tania ; Ostacolo, Carmine ; Piperno, Anna ; Iraci, Nunzio ; Micale, Nicola</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c320t-9154522012d4c194d9bb021de38e7c2eeb3601103a9abae5a18321a3da9f3c783</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Animals</topic><topic>antiepileptic</topic><topic>Computer Simulation</topic><topic>Convulsions &amp; seizures</topic><topic>Crystal structure</topic><topic>Drug Discovery - methods</topic><topic>Epilepsy</topic><topic>Genes</topic><topic>Hormones</topic><topic>Humans</topic><topic>KCNQ</topic><topic>KCNQ2 Potassium Channel - chemistry</topic><topic>KCNQ2 Potassium Channel - genetics</topic><topic>KCNQ2 Potassium Channel - metabolism</topic><topic>KCNQ3 Potassium Channel - antagonists &amp; inhibitors</topic><topic>KCNQ3 Potassium Channel - chemistry</topic><topic>KCNQ3 Potassium Channel - genetics</topic><topic>KCNQ3 Potassium Channel - metabolism</topic><topic>Kinases</topic><topic>Kv7</topic><topic>molecular docking</topic><topic>molecular dynamics</topic><topic>Mutation</topic><topic>Neurological disorders</topic><topic>Physiology</topic><topic>Potassium</topic><topic>potassium channel</topic><topic>Proteins</topic><topic>Structure-Activity Relationship</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Stagno, Claudio</creatorcontrib><creatorcontrib>Mancuso, Francesca</creatorcontrib><creatorcontrib>Ciaglia, Tania</creatorcontrib><creatorcontrib>Ostacolo, Carmine</creatorcontrib><creatorcontrib>Piperno, Anna</creatorcontrib><creatorcontrib>Iraci, Nunzio</creatorcontrib><creatorcontrib>Micale, Nicola</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>Directory of Open Access Journals</collection><jtitle>Molecules (Basel, Switzerland)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Stagno, Claudio</au><au>Mancuso, Francesca</au><au>Ciaglia, Tania</au><au>Ostacolo, Carmine</au><au>Piperno, Anna</au><au>Iraci, Nunzio</au><au>Micale, Nicola</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>In Silico Methods for the Discovery of Kv7.2/7.3 Channels Modulators: A Comprehensive Review</atitle><jtitle>Molecules (Basel, Switzerland)</jtitle><addtitle>Molecules</addtitle><date>2024-07-08</date><risdate>2024</risdate><volume>29</volume><issue>13</issue><spage>3234</spage><pages>3234-</pages><issn>1420-3049</issn><eissn>1420-3049</eissn><abstract>The growing interest in Kv7.2/7.3 agonists originates from the involvement of these channels in several brain hyperexcitability disorders. In particular, Kv7.2/7.3 mutants have been clearly associated with epileptic encephalopathies (DEEs) as well as with a spectrum of focal epilepsy disorders, often associated with developmental plateauing or regression. Nevertheless, there is a lack of available therapeutic options, considering that retigabine, the only molecule used in clinic as a broad-spectrum Kv7 agonist, has been withdrawn from the market in late 2016. This is why several efforts have been made both by both academia and industry in the search for suitable chemotypes acting as Kv7.2/7.3 agonists. In this context, in silico methods have played a major role, since the precise structures of different Kv7 homotetramers have been only recently disclosed. In the present review, the computational methods used for the design of Kv.7.2/7.3 small molecule agonists and the underlying medicinal chemistry are discussed in the context of their biological and structure-function properties.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>38999185</pmid><doi>10.3390/molecules29133234</doi><orcidid>https://orcid.org/0000-0002-6592-4373</orcidid><orcidid>https://orcid.org/0000-0002-1359-8684</orcidid><orcidid>https://orcid.org/0000-0002-9294-6033</orcidid><orcidid>https://orcid.org/0000-0003-3715-8680</orcidid><orcidid>https://orcid.org/0000-0002-7994-8253</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1420-3049
ispartof Molecules (Basel, Switzerland), 2024-07, Vol.29 (13), p.3234
issn 1420-3049
1420-3049
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_81562414ff3f4ae3b8d16f1636c21cc4
source PubMed (Medline); Publicly Available Content Database
subjects Animals
antiepileptic
Computer Simulation
Convulsions & seizures
Crystal structure
Drug Discovery - methods
Epilepsy
Genes
Hormones
Humans
KCNQ
KCNQ2 Potassium Channel - chemistry
KCNQ2 Potassium Channel - genetics
KCNQ2 Potassium Channel - metabolism
KCNQ3 Potassium Channel - antagonists & inhibitors
KCNQ3 Potassium Channel - chemistry
KCNQ3 Potassium Channel - genetics
KCNQ3 Potassium Channel - metabolism
Kinases
Kv7
molecular docking
molecular dynamics
Mutation
Neurological disorders
Physiology
Potassium
potassium channel
Proteins
Structure-Activity Relationship
title In Silico Methods for the Discovery of Kv7.2/7.3 Channels Modulators: A Comprehensive Review
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T08%3A42%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=In%20Silico%20Methods%20for%20the%20Discovery%20of%20Kv7.2/7.3%20Channels%20Modulators:%20A%20Comprehensive%20Review&rft.jtitle=Molecules%20(Basel,%20Switzerland)&rft.au=Stagno,%20Claudio&rft.date=2024-07-08&rft.volume=29&rft.issue=13&rft.spage=3234&rft.pages=3234-&rft.issn=1420-3049&rft.eissn=1420-3049&rft_id=info:doi/10.3390/molecules29133234&rft_dat=%3Cproquest_doaj_%3E3079857906%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c320t-9154522012d4c194d9bb021de38e7c2eeb3601103a9abae5a18321a3da9f3c783%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3079208192&rft_id=info:pmid/38999185&rfr_iscdi=true